Drugs that contain Prasterone

1. Intrarosa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8629129 MILLICENT Pharmaceutical compositions
Aug, 2028

(4 years from now)

US8957054 MILLICENT Pharmaceutical compositions
Jan, 2030

(5 years from now)

US8268806 MILLICENT Pharmaceutical compositions
Mar, 2031

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 16, 2021

NCE-1 date: 16 November, 2020

Market Authorisation Date: 16 November, 2016

Treatment: Intravaginal prasterone (dehydroepiandrosterone) at a daily dose of 6.5mg for the treatment of dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause


More Information on Dosage

INTRAROSA family patents

Family Patents